Fig. 4. Paclitaxel promotes the expression of invasive isoforms of MENA in the primary breast cancer microenvironment. Paclitaxel promotes the expression.

Slides:

Advertisements

Similar presentations

Fig. 3. Paclitaxel promotes TMEM-dependent vascular permeability, cancer cell dissemination, and metastasis in breast cancer. Paclitaxel promotes TMEM-dependent.

Advertisements

Fig. 1. Paclitaxel delays tumor growth and promotes infiltration of TIE2hi/VEGFhi macrophages and TMEM assembly. Paclitaxel delays tumor growth and promotes.

Immunologic responses after the MN-mediated cancer immunotherapy.

Self-folding triangular devices at two scales.

TPAD controller performance for three force components.

FIP200 maintains microRNA1198-5p expression via Ago2 in naïve T cells.

Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. Antitumor effect of local cancer immunotherapy treatment toward.

Longitudinal analysis of ZIKV E–specific memory B cell responses in the DENV-experienced donors. Longitudinal analysis of ZIKV E–specific memory B cell.

Regulatory CD4+ T cell–derived IL-10 is important for B cell differentiation and the GC response. Regulatory CD4+ T cell–derived IL-10 is important for.

Examples of AEGIS autonomous target selection.

Fig. 7. NAC in breast cancer patients promotes TMEM assembly and increased MENAINV expression. NAC in breast cancer patients promotes TMEM assembly and.

Ex vivo testing of the soft robotic devices.

VH usage of cross-reactive B cells induced by H5N1 or H7N9 vaccination

Characterization of the light-responsive transdermal MNs.

Fig. 7 Correlation of NHP and human ISGs.

Neutrophil recruitment to the colonic lamina propria depends on CD4+ T cells. Neutrophil recruitment to the colonic lamina propria depends on CD4+ T cells.

Fig. 5 Correlation of RNA expression and protein abundance.

Neutrophil depletion ameliorates colitis in Cx3cr1cre:Il10rafl/fl BM chimeras. Neutrophil depletion ameliorates colitis in Cx3cr1cre:Il10rafl/fl BM chimeras.

PD-L1 selectively marks circulating NCMs.

Fig. 5 Hypoxic tumors from obese mice associate with increased production of IL-6 by adipocytes and myeloid cells. Hypoxic tumors from obese mice associate.

Fig. 1. Generation of the ΔEx50 mouse model.

FIP200 maintains microRNA1198-5p expression via Ago2 in naïve T cells.

Fig. 1 ZIKV RNA in blood and tissues.

Fig. 7 Bacterial dependency networks in IgA deficiency and HDs.

Fig. 2 Preserved long-term functionality of the TEHVs over 1-year follow-up as assessed by ICE and cardiac MRI flow measurements. Preserved long-term functionality.

Fig. 6. Nontaxane chemotherapies induce TMEM-dependent prometastatic changes in the breast cancer microenvironment. Nontaxane chemotherapies induce TMEM-dependent.

Fig. 1 Examples of experimental stimuli and behavioral performance.

Fig. 5. In vivo characterization of adipogenesis by CT.

Fig. 3 NK cells are enriched in ICB-sensitive tumors in mouse models and patients and are required for response. NK cells are enriched in ICB-sensitive.

Fig. 4 Device accuracy results (n = 32 users).

Fig. 1. Potent and selective down-regulation of KRAS mRNA and protein by AZD4785 in vitro and in vivo. Potent and selective down-regulation of KRAS mRNA.

Fig. 1 Inbred mouse strains carrying monoclonal tumors display a symmetrical yet disparate response to ICB, associated with a distinctive gene signature.

Fig. 4 Rational therapeutic modulation of the tumor microenvironment sensitizes tumors to ICB. Rational therapeutic modulation of the tumor microenvironment.

Fig. 3 BMS blocks functional responses in primary immune cells driven by IL-23 and IL-12. BMS blocks functional responses in primary immune.

Fig. 2 Inflammatory pathways with STAT1 as a key regulator are enriched in ICB responsive tumors in mouse models and patients. Inflammatory pathways with.

BMS blocks functional responses in primary immune cells driven by IFNα

Fig. 1 Genes up-regulated in Zic5 KO cells correlate with the increased glycolytic state. Genes up-regulated in Zic5 KO cells correlate with the increased.

Tfr cells respond better to immunization with self-antigens than with foreign antigens. Tfr cells respond better to immunization with self-antigens than.

Fig. 6 RUNX/CBFB interaction inhibitor, Ro5-3335, significantly decreases mouse neurofibroma growth in vivo. RUNX/CBFB interaction inhibitor, Ro5-3335,

Fig. 4 Control analyses ensured that the relation between rotational acceleration and changes in FA does not depend on thresholds. Control analyses ensured.

AEGIS autonomous targeting process.

Examples of AEGIS autonomous target selection.

Fig. 3 Transcriptional changes in dKO mice.

Fig. 3 Local Maraba treatment of TNBC tumors provides long-term systemic protection. Local Maraba treatment of TNBC tumors provides long-term systemic.

Fig. 3 Production of protein and Fe(II) at the end of growth correlated with increasing concentrations of ferrihydrite in the media that contained 0.2.

PD and efficacy of AZD4785 in KRAS mutant lung cancer xenograft models

Fig. 1 Crohn’s disease association within the LRRK2 locus.

Pharmacological targeting of CDs promotes response to KRASG12C inhibition in vivo. Pharmacological targeting of CDs promotes response to KRASG12C inhibition.

Fig. 3 LRRK2 activation in nigrostriatal dopamine neurons in two rat models of PD. LRRK2 activation in nigrostriatal dopamine neurons in two rat models.

Immune evasion occurs independently of perforin-mediated killing.

Fig. 2 Effect of CSF sTREM2– and CSF sTREM2–to–p-tau181 ratio on changes in cognition. Effect of CSF sTREM2– and CSF sTREM2–to–p-tau181 ratio on changes.

Fig. 2 Increasing KLF17, CDH1, and LASS2 expression reduced malignant progression and promoted apoptosis of tumor cells. Increasing KLF17, CDH1, and LASS2.

Fig. 8. TIE2 inhibitor rebastinib eliminates the prometastatic effects of paclitaxel. TIE2 inhibitor rebastinib eliminates the prometastatic effects of.

Fig. 5. High burdens of AA signature mutations and predicted immunogenicity in Taiwan HCCs. High burdens of AA signature mutations and predicted immunogenicity.

Fig. 3 Characterization of SGN responses to optogenetic stimulation.

Fig. 1. Paclitaxel delays tumor growth and promotes infiltration of TIE2hi/VEGFhi macrophages and TMEM assembly. Paclitaxel delays tumor growth and promotes.

Fig. 2 BX795 is nontoxic to HCE cells at therapeutic concentration.

Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex.

Fig. 1 RNA methyltransferase METTL14 and demethylase ALKBH5 promote growth and invasion of breast cancer cells. RNA methyltransferase METTL14 and demethylase.

Fig. 3. Paclitaxel promotes TMEM-dependent vascular permeability, cancer cell dissemination, and metastasis in breast cancer. Paclitaxel promotes TMEM-dependent.

Fig. 5 LASV replication in cynomolgus monkeys.

Fig. 1 Isopropanol tolerance variation among E. faecium isolates.

Circadian gene expression in ILC3s is associated with rhythmic cytokine expression. Circadian gene expression in ILC3s is associated with rhythmic cytokine.

Fig. 4 Gallium increases P. aeruginosa sensitivity to peroxides.

Fig. 4 The abundance of Bifidobacterium in breast-fed infant guts is associated with FL transporter genes. The abundance of Bifidobacterium in breast-fed.

Fig. 8 Immune correlates of protection.

Fig. 3 Gene expression analysis in 48-plex drug treatment experiments.

PD and efficacy of AZD4785 in a KRAS wild-type lung cancer PDX model

Fig. 5. Paclitaxel promotes breast cancer cell dissemination and metastasis in a MENA-dependent manner. Paclitaxel promotes breast cancer cell dissemination.

Fig. 2 Astrocyte-specific AAV2/5 RiboTag.

Presentation transcript:

Fig. 4. Paclitaxel promotes the expression of invasive isoforms of MENA in the primary breast cancer microenvironment. Paclitaxel promotes the expression of invasive isoforms of MENA in the primary breast cancer microenvironment. (A to D) Gene expression of MENA or MENA isoforms (real-time RT-PCR) after RNA extraction from FFPE tumors. Gene expression of Pan-Mena (A), Mena11a (B), MenaCalc (C), and MenaINV (D) indicated. Mann-Whitney U test. NS, not significant. (E and F) Correlations of MenaCalc with TMEM and MenaINV gene expression with TMEM in the PyMT spontaneous (E) and HT17 xenograft (F) tumors. R2 = Pearson’s coefficient of determination; filled circles, control; open circles, paclitaxel. (G) MENAINV protein expression visualized by MENAINV IF and DAPI in PyMT spontaneous and HT17 xenograft tumors, treated with paclitaxel or vehicle control. Scale bar, 100 μm. (H) Quantification of the MENAINV-positive area (%) in tumors shown in (G). Mann-Whitney U test. (I) Correlation of MENAINV-positive area (%) with TMEM score in the PyMT spontaneous (top plot) and HT17 xenograft (bottom plot) models. R2 = Pearson’s coefficient of determination; filled circles, control; open circles, paclitaxel. George S. Karagiannis et al., Sci Transl Med 2017;9:eaan0026 Copyright © 2017 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works